Forma To Play To Its Strengths WIth Genentech Deal
START-UP July 2011, Vol. 16, No. 7
Venture Round / Word Count: 1626 / Article # 2011900161
Executive Summary
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
$85.00
Buy Now
For $85.00, purchase this 1626-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.